abstract |
The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and salts or synthetic and / or chemically modified derivatives thereof for the prevention or treatment of HMGB1-related lesions. In particular, the present invention relates to the use of K-252a for the prevention or treatment of restenosis. |